サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1298705

がん免疫療法市場：世界の産業動向、シェア、規模、成長機会、2023-2028年予測

Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 145 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
がん免疫療法市場：世界の産業動向、シェア、規模、成長機会、2023-2028年予測
出版日: 2023年06月14日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん免疫療法市場規模は2022年に1,067億米ドルに達しました。今後、IMARC Groupは、市場は2023年から2028年の間に8.8%の成長率（CAGR）を示し、2028年までに1,820億米ドルに達すると予測しています。がん患者数の増加、有利な政府の取り組み、医療保険の幅広い利用可能性などが市場を牽引する主な要因です。

がんとは、体内の細胞の一部が制御不能に増殖し、体のいくつかの部位に広がる病気を指します。アルコールやタバコの摂取、不健康な食事、大気汚染、運動不足などが原因で発症します。不安、抑うつ、死への恐怖、痛み、ストレス、自殺願望など、深刻な健康問題を引き起こすこともあります。がんは免疫療法によって治療することができます。免疫療法は、がん細胞が発現するタンパク質と結合し、その機能を阻害する抗体からなります。がん免疫療法は、異常ながん細胞を検出し破壊する免疫系を強化します。その上、他の治療法と比べて副作用が少なく、がん細胞が発生する可能性を減らすことができます。その結果、がん免疫療法は肺がん、乳がん、大腸がん、メラノーマ、前立腺がん、頭頸部がん、甲状腺がん、腎臓がん、肝臓がん、子宮頸がん、膀胱がん、卵巣がん、皮膚がんなどの治療に広く利用されています。

がん免疫療法の市場動向と促進要因：

現在、世界中の個人の間で、栄養バランスの悪い食事や有害物質の摂取が原因でがん患者が増加していることは、市場にプラスの影響を与える主要因の一つです。加えて、世界中の大衆の間で様々ながん治療の選択肢に対する認識が高まっていることも、市場の成長に寄与しています。これとは別に、がん免疫療法は抗腫瘍療法に比べて無増悪生存期間（PFS）と全生存期間（OS）の延長をもたらすことから、その利用が拡大しており、市場の見通しを明るいものにしています。さらに、医療保険が広く普及し、利用しやすくなっていることに加え、医療費支出が増加していることも、業界の投資家に有利な成長機会をもたらしています。さらに、世界中の大衆の間で副作用の少ない治療ソリューションに対する需要が高まっています。これに加え、新規免疫療法の承認が進み、がん免疫療法の採用が増加していることが、市場の成長を後押ししています。これに伴い、各国の行政機関や非営利団体が、がん予防に関する世界の認識を広めることでがん免疫療法の採用を奨励していることも、市場の成長を後押ししています。さらに、効率的に病気を治療するためのがん治療療法における様々な技術的進歩が、市場の成長を強化しています。

本レポートで扱う主な質問

  • 世界のがん免疫療法市場はこれまでどのように推移してきたか？
  • 世界のがん免疫療法市場における市場促進要因、市場抑制要因、市場機会は何か？
  • それぞれの促進要因、抑制要因、機会が世界のがん免疫療法市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的ながん免疫療法市場はどの国か？
  • 治療タイプ別の市場内訳は？
  • がん免疫療法市場で最も魅力的な治療タイプはどれか？
  • 用途別の市場内訳は？
  • がん免疫療法市場で最も魅力的なアプリケーションはどれか？
  • エンドユーザー別の市場内訳は？
  • がん免疫療法市場において最も魅力的なエンドユーザーはどこか？
  • 世界のがん免疫療法市場の競争構造は？
  • 世界のがん免疫療法市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 がん免疫療法の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • モノクローナル抗体
    • 市場動向
    • 市場予測
  • がんワクチン
    • 市場動向
    • 市場予測
  • チェックポイント阻害剤
    • 市場動向
    • 市場予測
  • 免疫調節薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • 肺がん
    • 市場動向
    • 市場予測
  • 乳がん
    • 市場動向
    • 市場予測
  • 大腸がん
    • 市場動向
    • 市場予測
  • メラノーマ
    • 市場動向
    • 市場予測
  • 前立腺がん
    • 市場動向
    • 市場予測
  • 頭頸部がん
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • がん研究センター
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド市場
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要プレーヤー
  • 主要プレーヤーのプロファイル
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck KGAA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Seagen Inc.
図表

List of Figures

  • Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2022
  • Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2022
  • Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2022
  • Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
  • Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
  • Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million US$), 2023-2028
  • Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
  • Table 7: Global: Cancer Immunotherapy Market: Key Players
目次
Product Code: SR112023A5095

The global cancer immunotherapy market size reached US$ 106.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 182.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028. The growing number of cancer cases, favorable government initiatives, and wide availability of medical insurance represent some of the key factors driving the market.

Cancer refers to a disease wherein some of the cells in the body grow uncontrollably and spread across several body parts. It is caused by alcohol or tobacco consumption, an unhealthy diet, air pollution, and physical inactivity. It can lead to severe health problems, such as anxiety, depression, fear of death, pain, stress, and suicidal thoughts among individuals. It can be treated through immunotherapy, which comprises antibodies that bind, and inhibit the function of proteins expressed by cancer cells. Cancer immunotherapy assists in boosting the immune system to detect and destroy abnormal cancer cells among individuals. Besides this, it causes fewer side effects as compared to other treatment options and reduces the chances of occurring cancerous cells. As a result, cancer immunotherapy is widely utilized to treat lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers among individuals across the globe.

Cancer Immunotherapy Market Trends and Drivers:

At present, the increasing number of cancer cases due to the poor balanced diet and consumption of toxic substances among individuals around the world represents one of the major factors influencing the market positively. In addition, the rising awareness about various cancer treatment options among the masses across the globe is contributing to the market growth. Apart from this, the growing utilization of cancer immunotherapies, as they provide prolonged progression-free survival (PFS) and overall survival (OS) compared to anti-tumor therapies, is offering a positive market outlook. Moreover, the wide availability and easy access to medical insurance, along with the increasing healthcare expenditure, is offering lucrative growth opportunities to industry investors. In addition, there is a rise in the demand for treatment solutions with fewer side effects among the masses around the world. This, coupled with the growing adoption of cancer immunotherapies due to the increasing approval for novel immunotherapies, is bolstering the growth of the market. In line with this, governing agencies and non-profit organizations of various countries are encouraging the adoption of cancer immunotherapy by spreading awareness about cancer prevention worldwide is impelling the growth of the market. Furthermore, various technological advancements in cancer treatment therapies to efficiently treat the disease are strengthening the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer immunotherapy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy type, application and end user.

Therapy Type Insights:

Monoclonal Antibodies

Cancer Vaccines

Checkpoint Inhibitors

Immunomodulators

Others

The report has provided a detailed breakup and analysis of the cancer immunotherapy market based on the therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others. According to the report, monoclonal antibodies represented the largest segment.

Application Insights:

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and Neck Cancer

Others

A detailed breakup and analysis of the cancer immunotherapy market based on the application has also been provided in the report. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. According to the report, lung cancer accounted for the largest market share.

End User Insights:

Hospitals

Cancer Research Centers

Clinics

Others

A detailed breakup and analysis of the cancer immunotherapy market based on the end user has also been provided in the report. This includes hospitals, cancer research centers, clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy. Some of the factors driving the North America cancer immunotherapy market included the growing number of patients suffering from cancer, rising development of bioinformatic tools, favorable government initiatives, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global cancer immunotherapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy. Some of the factors driving the North America cancer immunotherapy market included the growing number of patients suffering from cancer, rising development of bioinformatic tools, favorable government initiatives, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global cancer immunotherapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global cancer immunotherapy market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global cancer immunotherapy market?
  • What is the impact of each driver, restraint, and opportunity on the global cancer immunotherapy market?
  • What are the key regional markets?
  • Which countries represent the most attractive cancer immunotherapy market?
  • What is the breakup of the market based on the therapy type?
  • Which is the most attractive therapy type in the cancer immunotherapy market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the cancer immunotherapy market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the cancer immunotherapy market?
  • What is the competitive structure of the global cancer immunotherapy market?
  • Who are the key players/companies in the global cancer immunotherapy market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Cancer Immunotherapy Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Therapy Type

  • 6.1  Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Checkpoint Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4  Immunomodulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5  Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7   Market Breakup by Application

  • 7.1  Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Breast Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Colorectal Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Melanoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5  Prostate Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6  Head and Neck Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7  Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8   Market Breakup by End User

  • 8.1  Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Cancer Research Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4  Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10  SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2  AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3  Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4  Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5  Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6  F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7  GlaxoSmithKline Plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8  Johnson & Johnson
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9  Merck KGAA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10  Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11  Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12  Sanofi
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13  Seagen Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis